Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program

Second recent transaction with Bravos Biosciences consolidates development of Arsanis gram-negative mAb candidates with global experts in anti-infective drug development

June 14, 2018
Arsanis Biosciences GmbH

WALTHAM, Mass. and VIENNA, Austria, June 14, 2018 (GLOBE NEWSWIRE) -- Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that it has entered into an agreement under which BB200, LLC, a portfolio company of Bravos Biosciences, LLC, has secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license to selected monoclonal antibodies (mAbs) targeting K. pneumoniae that were discovered by Arsanis in its ASN300 program, including lead preclinical development candidate, ASN-5. In April 2018, Arsanis entered into a similar agreement for its ASN200 program, targeting E. coli, with Bravos Biosciences subsidiary BB100, LLC.

Full Press Release available here